Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631397 | 0.93 | AGTR1 (0.40) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL166867 | 0.89 | AGTR2 (0.56) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL4373827 | 0.85 | ABCB11 (0.55) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL8502175 | 0.84 | ALOX15 (0.34) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL6953505 | 0.83 | AGTR1 (0.51) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL9197447 | 0.82 | — | — | |
| SCHEMBL9192379 | 0.81 | PPARG (0.46) | PPARG | |
| SCHEMBL8635506 | 0.81 | AGTR2 (0.32) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL3979280 | 0.81 | AGTR2 (0.40) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL3975130 | 0.80 | AGTR2 (0.42) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | claimed |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-11-08 | — | — | US | claimed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | claimed |
| US-20120094913-A1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110046188-A1 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS | BETHESDA PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7867991-B2 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | BETHESDA PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1886683-B1 | Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure | BETHESDA PHARMACEUTICALS INC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7812046-B2 | PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20080242712-A1 | Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1886683-A1 | Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6232334-B1 | HAVE POTENT ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND ANTIHYPERTENSIVE ACTIVITY, FOR TREATING CIRCULATORY SYSTEM DISEASES SUCH AS HYPERTENSIVE DISEASES, HEART DISEASES, STROKES, CEREBRAL APOPLEXY AND NEPHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6004989-A | ETHYL 2-ETHOXY-1-(2'-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL) BENZIMIDAZOLE-7-CARBOXYLATE AND SALTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5962491-A | ANGIOTENSIN ANTAGONIST, HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, STROKES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5703110-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| US-5401764-A | Hypotensive agents or cardiovascular disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5328919-A | Antagonist of Angiotensin for cardiovascular disorders and hypotensive | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| US-5328919-A | Antagonist of Angiotensin for cardiovascular disorders and hypotensive | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242712-A1 | Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | AGTR2 6/4885CYP3A4 3345/4885ADORA3 811/4885 |
| US-20110046188-A1 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS | HDLBP, PPARA, PPARG | AGTR2 8/4885CYP3A4 1642/4885ADORA3 1116/4885 |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | AGTR1, REN, AGTR2 | AGTR2 3/4885CYP3A4 1603/4885ADORA3 1145/4885 |
| US-20120094913-A1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | PPARA, PPARG, PPARD | AGTR2 5/4885CYP3A4 3507/4885ADORA3 748/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | AGTR2 11/4885CYP3A4 270/4885ADORA3 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.